US Federal Trade Commission Sues CVS Health, Cigna, UnitedHealth's Pharmacy Benefit Managers For Inflating Insulin Prices
On Friday, the Federal Trade Commission (FTC) filed a formal complaint against three major pharmacy benefit managers (PBMs)—CVS Health Inc’s (NYSE:CVS) Caremark, Cigna Corp’s (NYSE:CI) Express Scripts,
Danish drugmaker Novo Nordisk expects its diabetes drug Ozempic will "very likely" be on the U.S. government's 2027 list of ...
KCEN-TV Waco-Temple-Bryan on MSN4d
'It's frustrating' | Brazos Valley man says GLP-1 medications continue to be in short supply for diabeticsThe demand for medications like Ozempic continues to cause shortages for both those seeking weight loss and patients with ...
In August 2023, the U.S. Department of Health and Human Services announced the first 10 drugs covered under Medicare Part D ...
Weight loss drugs have gained attention as a tool to help combat obesity, but understanding how they work, who they’re for, ...
A new study found a link between SGLT-2 inhibitors and a significantly lower risk of dementia in people with diabetes. Here's ...
Millions of Americans with diabetes need insulin to survive, yet for many of these vulnerable patients, their insulin drug ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback